{"id":509866,"date":"2025-08-05T00:00:00","date_gmt":"2025-08-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0030-2025-biopharma-psoriatic-arthritis-access-and-reimbursement-access-reimbursement-psoriatic-arthritis-us\/"},"modified":"2026-03-31T10:25:30","modified_gmt":"2026-03-31T10:25:30","slug":"acreim0030-2025-biopharma-psoriatic-arthritis-access-and-reimbursement-access-reimbursement-psoriatic-arthritis-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0030-2025-biopharma-psoriatic-arthritis-access-and-reimbursement-access-reimbursement-psoriatic-arthritis-us\/","title":{"rendered":"Psoriatic Arthritis &#8211; Access and Reimbursement &#8211; Access &#038; Reimbursement &#8211; Psoriatic Arthritis (US)"},"content":{"rendered":"<p>The <abbr title=\"psoriatic arthritis\">PsA<\/abbr> therapy market is undergoing significant transformation with the emergence of new treatment options, intensifying competition for favorable payer coverage. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, such as AbbVie\u2019s Humira, Amgen\u2019s Enbrel, and Johnson &#038; Johnson Innovative Medicine\u2019s Simponi, dominate as first-line biologics, driven by payer policies. However, non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr> biologics, including <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors like Novartis\u2019s Cosentyx and Lilly\u2019s Taltz, and <abbr title=\"interleukin\">IL<\/abbr>-23 inhibitors like Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya and AbbVie\u2019s Skyrizi, are expanding their presence despite stricter reimbursement hurdles. UCB\u2019s Bimzelx, an <abbr title=\"interleukin\">IL<\/abbr>-17A\/F dual inhibitor, offers a differentiated mechanism of action, though its uptake may be challenged by payer stringency and the need to demonstrate clear value. Meanwhile, the growing availability of adalimumab biosimilars and the emergence of oral agents are reshaping the competitive dynamics, with payers increasingly favoring cost-effective options. This report provides insights into how evolving payer policies influence prescribing patterns and explores strategies for marketers to navigate the challenging reimbursement landscape in the PsA\u00a0market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which are the patient-share leaders among PsA biologics, and which PsA agents do physicians and payers believe perform best on specific clinical and market access factors?<\/li>\n<li>What are the biggest reimbursement hurdles that PsA\u00a0drugs face?<\/li>\n<li>What are physicians\u2019 perceptions of the new and emerging agents like Bimzelx and Sotyktu, respectively, and how do payers anticipate covering these agents?<\/li>\n<li>What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW92978545 BCX8 round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n<p><strong>Primary research:<\/strong> Survey of 50 U.S. rheumatologists, 50 U.S. dermatologists, and 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s).<\/p>\n<p><strong>Fingertip Formulary: <\/strong>Formulary coverage by commercial plans covering more than 164.3 million lives nationally.<\/p>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key drugs<\/strong>: Remicade, Humira, biosimilar adalimumab, biosimilar infliximab, Xeljanz, Rinvoq, Skyrizi, Cosentyx, Taltz, Bimzelx, Tremfya, Skyrizi, and\u00a0Sotyktu.<\/p>\n","protected":false},"template":"","class_list":["post-509866","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-therapy-areas-rheumatology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/509866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/509866\/revisions"}],"predecessor-version":[{"id":575757,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/509866\/revisions\/575757"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=509866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}